279 research outputs found
The times have changed: molecular pathology is here to stay: A commentary on: Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma, by Lee et al. In this issue
Contains fulltext :
109946.pdf (publisher's version ) (Open Access)1 februari 201
Guidance for laboratories performing molecular pathology for cancer patients
Molecular testing is becoming an important part of the diagnosis of any patient with cancer. The challenge to laboratories is to meet this need, using reliable methods and processes to ensure that patients receive a timely and accurate report on which their treatment will be based. The aim of this paper is to provide minimum requirements for the management of molecular pathology laboratories. This general guidance should be augmented by the specific guidance available for different tumour types and tests. Preanalytical considerations are important, and careful consideration of the way in which specimens are obtained and reach the laboratory is necessary. Sample receipt and handling follow standard operating procedures, but some alterations may be necessary if molecular testing is to be performed, for instance to control tissue fixation. DNA and RNA extraction can be standardised and should be checked for quality and quantity of output on a regular basis. The choice of analytical method(s) depends on clinical requirements, desired turnaround time, and expertise available. Internal quality control, regular internal audit of the whole testing process, laboratory accreditation, and continual participation in external quality assessment schemes are prerequisites for delivery of a reliable service. A molecular pathology report should accurately convey the information the clinician needs to treat the patient with sufficient information to allow for correct interpretation of the result. Molecular pathology is developing rapidly, and further detailed evidence-based recommendations are required for many of the topics covered here
Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease
Important characteristics of chronic obstructive pulmonary disease (COPD)
include airway and vascular remodeling, the molecular mechanisms of which
are poorly understood. We assessed the role of fibroblast growth factors
(FGF) in pulmonary vascular remodeling by examining the expression pattern
of FGF-1, FGF-2, and the FGF receptor (FGFR-1) in peripheral area of lung
tissues from patients with COPD (FEV(1) < or = 75%; n = 15) and without
COPD (FEV(1) > or = 85%; n = 13). Immunohistochemical staining results
were evaluated by digital video image analysis as well as by manual
scoring. FGF-1 and FGFR-1 were detected in vascular smooth muscle (VSM),
airway smooth muscle, and airway epithelial cells. FGF-2 was localized in
the cytoplasm of airway epithelium and in the nuclei of airway smooth
muscle, VSM, and endothelial cells. In COPD cases, an unequivocal increase
in FGF-2 expression was observed in VSM (3-fold, P = 0.001) and
endothelium (2-fold, P = 0.007) of small pulmonary vessels with a luminal
diameter under 200 micro m. In addition, FGFR-1 levels were elevated in
the intima (1.5-fold, P = 0.05). VSM cells of large (> 200 micro m)
pulmonary vessels showed increased staining for FGF-1 (1.6-fold, P < 0.03)
and FGFR-1 (1.4-fold, P < 0.04) in COPD. Pulmonary vascular remodeling,
assessed as the ratio of alpha-smooth muscle actin staining and vascular
wall area with the lumen diameter, was increased in large vessels of
patients with COPD (P = 0.007) and was inversely correlated with FEV(1)
values (P < 0.007). Our results suggest an autocrine role of the
FGF-FGFR-1 system in the pathogenesis of COPD-associated vascular
remodeling
The Role of Dectin-2 for Host Defense Against Disseminated Candidiasis
Acknowledgments This work was supported by European Union ALLFUN (FP7/2007 2013, HEALTH-2010-260338) (Fungi in the setting of inflammation, allergy and autoimmune diseases: Translating basic science into clinical practices ‘‘ALLFUN’’) to D.C.I., F.C., C.F., M.G.N., and N.A.R.G. M.G.N and J.Q. were supported by a Vici grant of The Netherlands Organization of Scientific Research (to M.G.N.). M.G.N. was supported by an ERC Consolidator Grant (nr. 310372). N.A.R.G. was also supported by the Wellcome Trust (086827, 075470, 097377, & 101873).Peer reviewedPublisher PD
Genetic Association Analysis of the Functional c.714T>G Polymorphism and Mucosal Expression of Dectin-1 in Inflammatory Bowel Disease
Contains fulltext :
80614.pdf (publisher's version ) (Open Access)BACKGROUND: Dectin-1 is a pattern recognition receptor (PRR) expressed by myeloid cells that specifically recognizes beta-1,3 glucan, a polysaccharide and major component of the fungal cell wall. Upon activation, dectin-1 signaling converges, similar to NOD2, on the adaptor molecule CARD9 which is associated with inflammatory bowel disease (IBD). An early stop codon polymorphism (c.714T>G) in DECTIN-1 results in a loss-of-function (p.Y238X) and impaired cytokine responses, including TNF-alpha, interleukin (IL)-1beta and IL-17 upon in vitro stimulation with Candida albicans or beta-glucan. The aim of the present study was to test the hypothesis that the DECTIN-1 c.714T>G (p.Y238X) polymorphism is associated with lower disease susceptibility or severity in IBD and to investigate the level of dectin-1 expression in inflamed and non-inflamed colon tissue of IBD patients. METHODOLOGY: Paraffin embedded tissue samples from non-inflamed and inflamed colon of IBD patients and from diverticulitis patients were immunohistochemically stained for dectin-1 and related to CD68 macrophage staining. Genomic DNA of IBD patients (778 patients with Crohn's disease and 759 patients with ulcerative colitis) and healthy controls (n = 772) was genotyped for the c.714T>G polymorphism and genotype-phenotype interactions were investigated. PRINCIPAL FINDINGS: Increased expression of dectin-1 was observed in actively inflamed colon tissue, as compared to non-inflamed tissue of the same patients. Also an increase in dectin-1 expression was apparent in diverticulitis tissue. No statistically significant difference in DECTIN-1 c.714T>G allele frequencies was observed between IBD patients and healthy controls. Furthermore, no differences in clinical characteristics could be observed related to DECTIN-1 genotype, neither alone, nor stratified for NOD2 genotype. CONCLUSIONS: Our data demonstrate that dectin-1 expression is elevated on macrophages, neutrophils, and other immune cells involved in the inflammatory reaction in IBD. The DECTIN-1 c.714T>G polymorphism however, is not a major susceptibility factor for developing IBD
New developments in the pathology of malignant lymphoma: a review of the literature published from June–August 2016
- …